{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Study Design', 'The ATLAS-INH trial (ALN-AT3SC-003 [Sanofi Genzyme EFC14768]) is a multicenter,', 'multinational, randomized, open-label Phase 3 study designed to evaluate the efficacy and safety of', 'fitusiran in male patients aged >12 years, with hemophilia A or B and inhibitory antibodies to factor', 'VIII (FVIII) or factor IX (FIX), who are not receiving prophylactic therapy.', 'Eligible patients will be randomized in a 2:1 ratio to:', 'Fitusiran treatment arm: Fitusiran 80 mg administered subcutaneously (SC) as', 'prophylaxis once monthly, with use of on-demand BPAs for treatment of breakthrough', 'bleeding episodes', 'On-demand arm: On-demand BPAs for treatment of breakthrough bleeding episodes', 'On-demand use of BPAs is defined as the use of these agents as needed for episodic bleeding and not', 'on a regular regimen intended to prevent spontaneous bleeding. Throughout the study, patients in the', 'fitusiran treatment arm may receive on-demand treatment for breakthrough bleeding episodes with', 'BPAs, as appropriate.', 'Bleeding events and doses of BPAs administered during the conduct of the study will be recorded in', 'an electronic Diary (eDiary). Safety, quality of life, and pharmacodynamic, and pharmacokinetic data', 'will also be collected.', 'All patients will be treated for a total of 9 months; patients randomized to the fitusiran treatment arm', 'will receive a total of 9 SC injections of fitusiran. Because the full PD effect of fitusiran is not', 'achieved until approximately 28 days after receiving the first dose, efficacy will be assessed during', 'the final 8 months on study (Day 29 to Month 9).', 'An independent data monitoring committee (DMC) will oversee the safety and overall conduct of this', 'study. The DMC will perform periodic reviews of data during the course of the clinical trial, and on', 'an ad hoc basis for review of emergent safety data, as defined in the DMC Charter for this clinical', 'trial.', 'Patients from both the fitusiran and on-demand treatment arms who complete the study may be', 'eligible for participation in an open-label extension study. Following final fitusiran dose, for patients', 'in the fitusiran treatment arm patients who do not enroll in the extension study, AT activity level will', 'be monitored at monthly intervals until returning to an activity level of approximately 60% (per the', 'central laboratory) or per Investigator discretion in consultation with the study Medical Monitor.', 'Number of Planned Patients', 'Approximately 54 patients will be randomized, including approximately 5 patients with hemophilia B', 'and approximately 5 adolescents (12 to <18 years of age).', 'Diagnosis and Main Eligibility Criteria', 'This study will include males with severe hemophilia A or B with inhibitors, aged >12 years, who', 'have had a minimum of 6 bleeding episodes requiring BPA treatment within the last 6 months prior to', 'Screening. Diagnosis of severe hemophilia A or B will be based on a central laboratory measurement', 'or documented medical record evidence of FVIII level <1% or FIX level 2% at Screening.', 'Patients with inhibitors must have used bypass agents on demand to manage bleeding episodes for at', 'least the last 6 months prior to Screening and must meet one of the following Nijmegen-modified', 'Bethesda assay results criteria: 1) Inhibitor titer of >0.6 BU/mL at Screening, OR 2) Inhibitor titer of', '<0.6 BU/mL at Screening with medical record evidence of 2 consecutive titers >0.6 BU/mL, OR 3)', 'Inhibitor titer of <0.6 BU/mL at Screening with medical record evidence of anamnestic response.', 'Property of the Sanofi Group - strictly confidential', '9']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Investigational Product, Dose and Mode of Administration', 'Fitusiran is an SC administered N-acetylgalactosamine (GalNAc)-conjugated siRNA targeting liver-', 'expressed messenger RNA (mRNA) for AT.', 'Patients randomized to the fitusiran treatment arm will receive open label fitusiran 80 mg as an SC', 'injection once monthly, for a total of 9 months; dosing will begin on Day 1 of the treatment period.', 'Reference Therapy, Dose and Mode of Administration', 'Patients in on-demand arm will receive on-demand BPA therapy per Investigator discretion to treat', 'bleeding episodes from Day 1 through end of study. The protocol will recommend guidance for', 'patients in the fitusiran treatment arm for treatment of breakthrough bleeding episodes during the', 'fitusiran efficacy period.', 'Duration of Treatment', 'The duration of treatment with fitusiran is 9 months. The estimated total time on study, inclusive of', 'Screening, for each patient is up to 11 months for all patients who enroll in the extension study and', 'patients in the on-demand arm who do not enroll in the extension study. The estimated total time on', 'the study may be up to 17 months in fitusiran treatment arm patients who do not enroll in the', 'extension study due to the requirement for an additional 6 months of follow-up monitoring for AT', 'levels.', 'Statistical Methods', 'Sample Size Calculation', 'Assuming a mean ABR of 18 with standard deviation (SD) = 14 in the on-demand arm (patients', 'randomized to receive only BPAs) and a mean ABR of no more than 4 with SD = 6 in the fitusiran', 'treatment arm (patients randomized to receive fitusiran) in either the efficacy period or the treatment', 'period, with a sample size of 14 evaluable patients in the on-demand arm and approximately', '28 evaluable patients in the fitusiran treatment arm, it is projected that the study will have greater than', '90% power for testing treatment difference in mean ABRs. This power estimation was based on', 'negative binomial regression model with a 2-sided Type I error rate of 0.05. The planned sample size', 'is 54 randomized patients assuming a 20% drop-out rate.', 'Analyses', 'The primary analysis will be performed on the intent-to-treat (ITT) analysis set which includes all', 'randomized patients. The primary endpoint will be based on the bleeding episodes occurring in the', 'efficacy period (Day 29 to Day 246) including the data collected after discontinuation of', 'investigational medicinal product (IMP). To avoid confounding the treatment effect, bleeding data', 'during and after major surgery, AT administration, major trauma, or after initiation of prophylaxis', 'treatment with BPA will be excluded from the primary analysis.', 'The number of bleeding episodes will be analyzed using a negative binomial model with fixed effects', 'of treatment arm and the number of bleeding episodes in the 6 months prior to study entry (10 VS', '>10). The logarithm number of days that each patient spends in the efficacy period matching the', 'bleeding episode data being analyzed will be included as an offset variable to account for unequal', 'follow-up time due to early withdrawal or surgery. The ratio of the bleeding rate on fitusiran treatment', 'arm relative to the bleeding rate on the on-demand arm and its 95% confidence interval will be', 'presented. Sensitivity analyses will be performed to evaluate the impact of missing data under', 'different missing data mechanisms and details will be specified in the statistical analysis plan.', 'The bleeding episodes in the treatment period (Day 1 to Day 246), spontaneous bleeding episodes in', 'the efficacy period, joint bleeding episodes in the efficacy period, and the bleeding episodes in the', 'Property of the Sanofi Group - strictly confidential', '10']\n\n###\n\n", "completion": "END"}